{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:11:25Z","timestamp":1769731885018,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA121938"],"award-info":[{"award-number":["T32CA121938"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10549-020-06014-5","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T07:02:39Z","timestamp":1605164559000},"page":"551-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ductal carcinoma in situ in patients younger than 30\u00a0years: differences in adjuvant endocrine therapy and outcomes"],"prefix":"10.1007","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6909-2244","authenticated-orcid":false,"given":"Sasha R.","family":"Halasz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-4049","authenticated-orcid":false,"given":"Sarah L.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"6014_CR1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","volume":"1","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Giannakeas V et al (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1:888\u2013896. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2510","journal-title":"JAMA Oncol"},{"key":"6014_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jss.2018.05.007","volume":"231","author":"CE Jones","year":"2018","unstructured":"Jones CE, Richman J, Jackson BE et al (2018) Treatment patterns for ductal carcinoma in situ with close or positive mastectomy margins. J Surg Res 231:36\u201342. https:\/\/doi.org\/10.1016\/j.jss.2018.05.007","journal-title":"J Surg Res"},{"key":"6014_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10549-017-4436-9","volume":"166","author":"Y Sagara","year":"2017","unstructured":"Sagara Y, Freedman RA, Wong SM et al (2017) Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004\u20132013. Breast Cancer Res Treat 166:583\u2013592. https:\/\/doi.org\/10.1007\/s10549-017-4436-9","journal-title":"Breast Cancer Res Treat"},{"key":"6014_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32362","volume":"146","author":"MR Van Bockstal","year":"2020","unstructured":"Van Bockstal MR, Agahozo MC, Koppert LB, van Deurzen CHM (2020) A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int J Cancer 146:1189\u20131197. https:\/\/doi.org\/10.1002\/ijc.32362","journal-title":"Int J Cancer"},{"key":"6014_CR5","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1245\/s10434-017-5930-3","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hoskin TL, Day CN et al (2017) Factors influencing use of hormone therapy for ductal carcinoma in situ: a National Cancer Database Study. Ann Surg Oncol 24:2989\u20132998. https:\/\/doi.org\/10.1245\/s10434-017-5930-3","journal-title":"Ann Surg Oncol"},{"key":"6014_CR6","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1002\/cncr.24376","volume":"115","author":"H Nassar","year":"2009","unstructured":"Nassar H, Sharafaldeen B, Visvanathan K, Visscher D (2009) Ductal carcinoma in situ in African American versus Caucasian American women: analysis of clinicopathologic features and outcome. Cancer 115:3181\u20133188. https:\/\/doi.org\/10.1002\/cncr.24376","journal-title":"Cancer"},{"key":"6014_CR7","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1245\/s10434-017-5985-1","volume":"24","author":"EP Ward","year":"2017","unstructured":"Ward EP, Unkart JT, Bryant A et al (2017) Influence of distance to hospital and insurance status on the rates of contralateral prophylactic mastectomy, a National Cancer Data Base study. Ann Surg Oncol 24:3038\u20133047. https:\/\/doi.org\/10.1245\/s10434-017-5985-1","journal-title":"Ann Surg Oncol"},{"key":"6014_CR8","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1245\/s10434-016-5249-5","volume":"23","author":"PA Cronin","year":"2016","unstructured":"Cronin PA, Olcese C, Patil S et al (2016) Impact of age on risk of recurrence of ductal carcinoma in situ: outcomes of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 23:2816\u20132824. https:\/\/doi.org\/10.1245\/s10434-016-5249-5","journal-title":"Ann Surg Oncol"},{"key":"6014_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1200\/JCO.2000.18.2.296","volume":"18","author":"FA Vicini","year":"2000","unstructured":"Vicini FA, Kestin LL, Goldstein NS et al (2000) Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol Off J Am Soc Clin Oncol 18:296\u2013306. https:\/\/doi.org\/10.1200\/JCO.2000.18.2.296","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6014_CR10","doi-asserted-by":"publisher","unstructured":"Alvarado R, Lari SA, Roses RE et al (2012) Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19. https:\/\/doi.org\/10.1245\/s10434-012-2413-4","DOI":"10.1245\/s10434-012-2413-4"},{"key":"6014_CR11","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6","volume":"92","author":"Q Xiong","year":"2001","unstructured":"Xiong Q, Valero V, Kau V et al (2001) Female patients with breast carcinoma age 30 years and younger have a poor prognosis. Cancer 92:2523\u20132528. https:\/\/doi.org\/10.1002\/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6","journal-title":"Cancer"},{"key":"6014_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.breast.2011.05.002","volume":"20","author":"PA Francis","year":"2011","unstructured":"Francis PA (2011) Optimal adjuvant therapy for very young breast cancer patients. Breast 20:297\u2013302. https:\/\/doi.org\/10.1016\/j.breast.2011.05.002","journal-title":"Breast"},{"key":"6014_CR13","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.clbc.2017.08.001","volume":"18","author":"HL Park","year":"2018","unstructured":"Park HL, Chang J, Lal G et al (2018) Trends in treatment patterns and clinical outcomes in young women diagnosed with ductal carcinoma in situ. Clin Breast Cancer 18:e179\u2013e185. https:\/\/doi.org\/10.1016\/j.clbc.2017.08.001","journal-title":"Clin Breast Cancer"},{"key":"6014_CR14","doi-asserted-by":"publisher","unstructured":"Llarena NC, Estevez SL, Tucker SL, Jeruss JS (2015) Impact of fertility concerns on Tamoxifen initiation and persistence. J Natl Cancer Inst 107. https:\/\/doi.org\/10.1093\/jnci\/djv202","DOI":"10.1093\/jnci\/djv202"},{"key":"6014_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/tbj.12999","volume":"24","author":"A Voci","year":"2018","unstructured":"Voci A, Bandera B, Ho E et al (2018) Variations in cancer care for adolescents and young adults (AYAs) with ductal carcinoma in situ. Breast J 24:555\u2013560. https:\/\/doi.org\/10.1111\/tbj.12999","journal-title":"Breast J"},{"key":"6014_CR16","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K et al (2017) Using the national cancer database for outcomes research: a review. JAMA Oncol 3:1722\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905","journal-title":"JAMA Oncol"},{"key":"6014_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-016-3926-5","volume":"159","author":"BM Parsons","year":"2016","unstructured":"Parsons BM, Landercasper J, Smith AL et al (2016) 21-gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010\u20132013. Breast Cancer Res Treat 159:315\u2013326. https:\/\/doi.org\/10.1007\/s10549-016-3926-5","journal-title":"Breast Cancer Res Treat"},{"key":"6014_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","volume":"30","author":"DC Allred","year":"2012","unstructured":"Allred DC, Anderson SJ, Paik S et al (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol Off J Am Soc Clin Oncol 30:1268\u20131273. https:\/\/doi.org\/10.1200\/JCO.2010.34.0141","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6014_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.6004\/jnccn.2016.0118","volume":"14","author":"RM Kauffmann","year":"2016","unstructured":"Kauffmann RM, Goldstein L, Marcinkowski E et al (2016) Predictors of Antiestrogen recommendation in women with Estrogen receptor-positive ductal carcinoma in situ. J Natl Compr Cancer Netw 14:1081\u20131090. https:\/\/doi.org\/10.6004\/jnccn.2016.0118","journal-title":"J Natl Compr Cancer Netw"},{"key":"6014_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","volume":"208","author":"JL Gnerlich","year":"2009","unstructured":"Gnerlich JL, Deshpande AD, Jeffe DB et al (2009) Elevated breast cancer mortality in young women (<40 years) compared with older women is attributed to poorer survival in early stage disease. J Am Coll Surg 208:341\u2013347. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2008.12.001","journal-title":"J Am Coll Surg"},{"key":"6014_CR21","doi-asserted-by":"publisher","unstructured":"Fredholm H, Eaker S, Frisell J et al (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4. https:\/\/doi.org\/10.1371\/journal.pone.0007695","DOI":"10.1371\/journal.pone.0007695"},{"key":"6014_CR22","series-title":"Data points publication series","volume-title":"Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer: data points # 14","author":"BA Virnig","year":"2011","unstructured":"Virnig BA, Torchia MT, Jarosek SL et al (2011) Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer: data points # 14, Data points publication series. Agency for Healthcare Research and Quality (US), Rockville"},{"key":"6014_CR23","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al (2019) Randomized placebo controlled trial of low-dose Tamoxifen to prevent local and contralateral recurrence in breast intraepithelial Neoplasia. J Clin Oncol 37:1629\u20131637. https:\/\/doi.org\/10.1200\/JCO.18.01779","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-020-06014-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T17:24:01Z","timestamp":1616606641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-020-06014-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["6014"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-06014-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sasha Halasz declares that she has no conflict of interest. Thomas O\u2019Keefe declares that he has no conflict of interest. Anne Wallace declares that she has no conflict of interest. SLB has a family member with an equity interest in Viewpoint Medical, Inc., a company that has no benefit from the research results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. The UCSD HRPP\/IRB deferred need for approval due to use of public, de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}